Inner ear drug delivery for auditory applications.
Many inner ear disorders cannot be adequately treated by systemic drug delivery. A blood-cochlear barrier exists, similar physiologically to the blood-brain barrier, which limits the concentration and size of molecules able to leave the circulation and gain access to the cells of the inner ear. However, research in novel therapeutics and delivery systems has led to significant progress in the development of local methods of drug delivery to the inner ear. Intratympanic approaches, which deliver therapeutics to the middle ear, rely on permeation through tissue for access to the structures of the inner ear, whereas intracochlear methods are able to directly insert drugs into the inner ear. Innovative drug delivery systems to treat various inner ear ailments such as ototoxicity, sudden sensorineural hearing loss, autoimmune inner ear disease, and for preserving neurons and regenerating sensory cells are being explored.
Charles Stark Draper Laboratory, 555 Technology Square, Cambridge, MA 02139, USA. eswan@draper.com
Erin E Leary
EE
Swan
Mark J
MJ
Mescher
William F
WF
Sewell
Sarah L
SL
Tao
Jeffrey T
JT
Borenstein
D000287:Administration, Topical; D000818:Animals; D003051:Cochlea / Q000378:metabolism; D016503:Drug Delivery Systems; D007758:Ear, Inner / Q000378:metabolism*; D006801:Humans; D007759:Labyrinth Diseases / Q000188:drug therapy*; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D010599:Pharmacokinetics; D014432:Tympanic Membrane / Q000378:metabolism
D004364:Pharmaceutical Preparations